Personalized nanomedicine: Future medicine for cancer treatment

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 201-202

  Shiekh, Farooq A ^a  

^a Department of Basic Medical Sciences Avalon University School of Medicine   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GENOMICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NANOMEDICINE; NANOTOXICOLOGY; PARTICLE SIZE; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; RISK BENEFIT ANALYSIS; TOXICOGENOMICS;

EID: 84872536507     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S41525     Document Type: Editorial

References (25)

1. Parkin DM. International variation. Oncogene. 2004;23:6329-6340.
2. Sugahara KN, Teesalu T, Karmali PP, etal. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031-1035.
3. Colditz GA, Sellers TA, Trapido E. Epidemiology - identifying the causes and preventability of cancer? Nat Rev Cancer. 2006;6:75-83.
4. Shiekh FA. Blood-brain barrier: a real obstacle for therapeutics. Int J Nanomedicine. 2012;7:4065-4066.
5. Horton JK, Wilson SH. Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res. November 27, 2012. [Epub ahead of print]
6. Horton JK, Gleason JF Jr, Klepin HD, Isom S, Fried DB, Geiger AM. Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma. Cancer. 2011;117:4033-4040.
7. Godat LN, Horton JK, Shen P, Stewart JH, Wentworth S, Levine EA. Recurrence after mastectomy for ductal carcinoma in situ. Am Surg. 2009;75:592-595.
8. Service RF. Materials and biology. Nanotechnology takes aim at cancer. Science. 2005;310:1132-1134.
9. Reed JC. Cancer. Priming cancer cells for death. Science. 2011;334: 1075-1076.
10. Ryan RJ, Bernstein BE. Molecular biology. Genetic events that shape the cancer epigenome. Science. 2012;336:1513-1514.
11. Cao Y, DePinho RA, Ernst M, Vousden K. Cancer research: past, present and future. Nat Rev Cancer. 2011;11:749-754.
12. Gewin V. Big opportunities in a small world. Nature. 2009;460: 540-541.
13. Hassan MH. Nanotechnology. Small things and big changes in the developing world. Science. 2005;309:65-66.
14. Sukhanova A, Even-Desrumeaux K, Kisserli A, et al. Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomedicine. 2012;8:516-525.
15. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653-664.
16. Prabhu P, Patravale V. The upcoming field of theranostic nanomedicine: an overview. J Biomed Nanotechnol. 2012;8:859-882.
17. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012;12:835-848.
18. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338:903-910.
19. Kozako T, Arima N, Yoshimitsu M, Honda SI, Soeda S. Liposomes and nanotechnology in drug development: focus on oncotargets. Int J Nanomedicine. 2012;7:4943-4951.
20. Meyer UA. Personalized medicine: a personal view. Clin Pharmacol Ther. 2012;91:373-375.
21. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011;17:297-303.
22. Shute N. Personalized medicine. Sci Am. 2012;306:44.
23. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat Nanotechnol. 2008;3:242-244.
24. Gershon D. Toxicogenomics gains impetus. Nature. 2002;415:4-5.
25. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009;8:213-225.